Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
How mid-tier CDMOs are catching up
For years, digital transformation in pharmaceutical manufacturing has been the domain of Big Pharma and the largest Contract Development and…
Ordering a vaccine that doesn’t exist?
Washington ordered a vaccine that doesn’t exist. Here’s what it would actually take to build it.
Trump’s MMR executive order is being covered as a political story. The more consequential question is a manufacturing one — and the answer from the only company that matters is: ten years, maybe more.
The anti-vaxxers who voted for Trump are now watching him mandate vaccines
The movement that spent years insisting vaccines were dangerous, unnecessary, and a tool of government overreach just got an unusual…
Who decides in the EU?
Out of five Croatians in Brussels, roughly one in five Croatians decided who would speak for the other four in…
Germany goes to Bangalore: Formycon’s India deal is the latest sign that biosimilar manufacturing is moving east — permanently
A Munich-based biosimilar developer just signed a strategic manufacturing partnership with an Indian CDMO. According to industry analysts, it is not the first such deal, and it will not be the last. The question is what Europe gets — and what it gives up — as the shift accelerates?
How the Hormuz blockade became a prolonged war: pharma’s supply nightmare deepens as truce fails and strait closes again
The 21-mile-wide waterway that supplies Europe’s medicine cabinet is not reopening — it is effectively closed once more, live maritime tracking data and intelligence reports show. The crisis that began in February has evolved into an active theatre of war with no clear end in sight.
Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30
Poolbeg Pharma (AIM: POLB) said on 13 July that the first patient has been dosed in its POLB 001 TOPICAL trial, according to the company’s RNS statement, and that University College London Hospital has now also been activated as a clinical trial site, with additional sites expected to open imminently. Investor reaction will hinge less on the milestone itself — dosing a first patient is table stakes for any trial — and more on what happens over the next six to eight weeks, since interim data is still on track for late summer.
The Rerouting of Europe‘s medicine cabinet: How the Iran war is reshaping pharmaceutical supply chains
By Pharmaceutical Daily Editorial Staff As the conflict in the Middle East enters its second month, the pharmaceutical industry across…
Light instead of antibiotics: Ondine’s Phase 3 trial is weeks away from results that could reshape surgical infection prevention
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.
Just a note about how AI is changing journalism
By Dino MustafićJust a note about how AI is changing journalism